Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 21. Analyst Tycho Peterson from Jefferies reiterated a Buy rating on the stock and has a $80.00 price target.
Tycho Peterson has given his Buy rating due to a combination of factors that highlight the potential growth and favorable positioning of Exact Sciences. The recent CMS transmittal has solidified the coverage and pay rate for Cologuard Plus, providing a clearer revenue outlook with an anticipated 4% incremental revenue increase in 2026 and 2027 compared to previous estimates. This development, alongside a modest sales valuation, enhances the company’s risk-reward profile.
Additionally, the company’s strategic initiatives such as the upcoming launch of Oncodetect MRD in the second quarter of 2025 and the multi-cancer early detection test in the third quarter are significant growth drivers. These launches, coupled with a strong commercial footprint and payer contracts, position Exact Sciences favorably in the market. The stock’s current trading discount compared to peers further supports the Buy rating, making it a top pick with a strong catalyst path.
According to TipRanks, Peterson is a 4-star analyst with an average return of 4.9% and a 50.32% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Exact Sciences, Bruker, and Thermo Fisher.
In another report released on March 17, BTIG also reiterated a Buy rating on the stock with a $65.00 price target.